Servier And Ideaya Biosciences Announced An Exclusive License Agreement For Darovasertib For Rare Eye Cancer, Servier Obtains Rights For Darovasertib Outside US, Ideaya Will Receive An Upfront Payment Of $210M And Up To $320 Million In Milestones, Plus Sales-based Royalties

Benzinga · 09/02/2025 10:05
  • Servier and IDEAYA Biosciences enter into an exclusive license agreement for regulatory and commercial rights to darovasertib outside the US
  • Darovasertib is a small molecule developed for patients with uveal melanoma, a rare type of eye cancer with high unmet medical need
  • IDEAYA will receive an upfront payment of $210 million and up to $320 million in regulatory and commercial milestones, plus double-digit royalties on net sales
  • IDEAYA and Servier will collaborate on the development of darovasertib and share the associated costs